By inhibiting IL-6, which plays a key role in the downstream inflammatory cascade,23 tocilizumab has a prominent effect on curtailing CRS without inhibiting CAR-T cell anti-tumor activity.24–27 Despite its clinical success, there are unknown factors that surround tocilizumab's use for the future. The gene discussed is IL6; the disease is congenital rubella syndrome.